Aslan Pharmaceuticals receives favorable opintion from EPO on farudodstat

ASLAN Pharmaceuticals announced it has received a favorable patentability opinion from the European Patent Office, EPO, acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043. “We are very pleased to have received a positive preliminary opinion from the EPO on the Composition of Matter patent application for farudodstat, and recognition that all of our claims were novel and inventive. If granted in the national stages, the new patent will extend the patent protection on farudodstat until at least 2043. This will significantly enhance the commercial exclusivity of farudodstat and is an important achievement in our plans to strengthen the patent protection for farudodstat in all key commercial territories. With so few treatment options available to alopecia areata patients, our ambition is to bring a safe and effective treatment option to patients,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.